KRAS and neoplasm: Mutations of TP53 and ZFHX4 amplifications were generally shared between primary tumor and PM, while CSMD3 mutations, CNVs were frequently discrepant, such as potentially targetable amplifications of CCNE1, MYC and KRAS (Fig. 1D).